PharmaNewsIntelligence#health
Blurring the line between GLP-1 compounders, counterfeiterstranslating…
Factuality: 80/100UnknownPharmaNewsIntelligence Press Group
Weak regulatory oversight has allowed 503A compounding facilities to abuse customization rules, blurring the line between GLP-1 compounders and unregulated drug manufacturers.